GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) Plus Chemotherapy for the Treatment of DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
June 07, 2023
June 07, 2023
LONDON, England, June 7 (TNSres) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on June 6, 2023:
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endom . . .
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endom . . .